Tikva Allocell Secures $8 Million Series A Financing to Advance Engineered Off-the-Shelf Cell Therapies for Solid Tumors
SINGAPORE and UNITED STATES — 22 JULY 2026 — Tikva Allocell today announced the successful closing of an $8 million Series
Corporate Presentation
Related Posts
The multifarious role of SerpinB9 armoring
CAR-T cell therapy has revolutionized cancer treatment, but its efficacy against solid tumors remains limited due to challenges like poor CAR-T cell in-vivo survival. Tikva’s engineered SB9 EBVST platform will not only address a major resistance mechanism axis but also opens doors to more effective CAR T cell therapies for solid tumors.